Vascular health and risk management
-
Vasc Health Risk Manag · Jan 2011
Randomized Controlled Trial Comparative StudyAmbulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
Stage 2 hypertension often requires combination antihypertensive therapy. Ambulatory blood pressure monitoring (ABPM) is a useful tool for assessing antihypertensive drugs and their combinations. ⋯ Initiating antihypertensive treatment with moderate doses of ARB/CCB with a diuretic is more effective in lowering nighttime and daytime ABP and reducing ABP load than a maximal dose of an ARB with a diuretic.
-
Vasc Health Risk Manag · Jan 2010
Randomized Controlled Trial Comparative StudyComparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.
The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients is not known. ⋯ Valsartan administered qd has a similar safety and tolerability profile with comparable 24-hour RAAS blockade, as assessed by increases in PRA, as bid dosing in patients with moderate to severe (NYHA class II-III) heart failure.
-
Vasc Health Risk Manag · Jan 2009
Randomized Controlled TrialEffects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts.
Acute renal failure is a common complication of cardiac surgery, with oxidants found to play an important role in renal injury. We therefore assessed whether the supplemental antioxidant vitamin E and the inhibitor of xanthine oxidase allopurinol could prevent renal dysfunction after coronary artery bypass graft (CABG) surgery. ⋯ Prophylactic treatment with vitamin E and allopurinol had no renoprotective effects in patients with pre-existing renal failure undergoing CABG surgery. Treatment with these agents, however, reduces the duration of ICU stay.